{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:54:58Z","timestamp":1790142898192,"version":"4.0.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T00:00:00Z","timestamp":1638057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Infectious Diseases Department of Verona University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Short-cycle therapy (SCT) is the administration of ART for 4 or 5 consecutive days a week, followed by 3 or 2 days off therapy. Its benefits include improving patient satisfaction and reducing ART toxicity and costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this observational study we included HIV-infected adults with a three-drug ART containing rilpivirine, a history of long-term virological suppression and no evidence of resistance to previous drug regimens. Patients switched to a SCT of 4 days on\/3 days off and were followed for 48 weeks with regular check-ups. The primary outcome was virological suppression; secondary outcomes were changes in CD4+ cells and rilpivirine plasma concentration, the occurrence of adverse events and resistance in the case of failure, and patient satisfaction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At week 48 no virological failure was observed, with a virological suppression rate of 30\/30 (100%). Three patients switched back to continuous therapy for other reasons, with an overall success rate of SCT of 30\/33 (90.9%, 95% CI = 81.24% to 100%). The CD4+ mean value increased by +64 cells\/mm3 (95% CI = \u221259 to +187 cells\/mm3; P = 0.052). No adverse events were observed and the mean total score in the satisfaction questionnaire was 57.7\/60 (96.22%). Rilpivirine plasma concentration was below the efficacy threshold in 71.3% of the samples, suggesting that the patients\u2019 characteristics, more than the drug\u2019s pharmacokinetics, played a role in maintaining virological suppression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>SCT with rilpivirine-containing regimens could be an effective alternative to continuous therapy in selected HIV-infected patients with previous long-term virological suppression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkab442","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:11:25Z","timestamp":1637093485000},"page":"747-752","source":"Crossref","is-referenced-by-count":5,"title":["Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on\/3 days off therapy"],"prefix":"10.1093","volume":"77","author":[{"given":"Dora","family":"Luise","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Vicenza Hospital, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Lattuada","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Diagnostic and Public Health, Integrated University Hospital of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Rizzardo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Internal Medicine Unit, Rovereto Hospital, Rovereto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Nicol\u00e8","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Vicenza Hospital, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Lambertenghi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Diagnostic and Public Health, Integrated University Hospital of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Coledan","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Rovigo Hospital, Rovigo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gambino","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Bolzano Hospital, Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-1723","authenticated-orcid":false,"given":"Rossella","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Division of Legal Medicine, Department of Diagnostic and Public Health, Integrated University Hospital of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Lanzafame","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Rovigo Hospital, Rovigo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Vento","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,28]]},"reference":[{"key":"2022022313001285400_dkab442-B1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1310\/hct0801-19","article-title":"Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study","volume":"8","author":"Cohen","year":"2007","journal-title":"HIV Clin Trials"},{"key":"2022022313001285400_dkab442-B2","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/S2352-3018(16)30054-6","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2\/3 trial","volume":"3","author":"BREATHER (PENTA 16) Trial Group","year":"2016","journal-title":"Lancet HIV"},{"key":"2022022313001285400_dkab442-B3","doi-asserted-by":"crossref","first-page":"e0196239","DOI":"10.1371\/journal.pone.0196239","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): extended follow-up results of a randomised, open-label, non-inferiority trial","volume":"13","author":"Turkova","year":"2018","journal-title":"PLoS One"},{"key":"2022022313001285400_dkab442-B4","doi-asserted-by":"crossref","first-page":"e012934","DOI":"10.1136\/bmjopen-2016-012934","article-title":"Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?","volume":"7","author":"Bernays","year":"2017","journal-title":"BMJ Open"},{"key":"2022022313001285400_dkab442-B5","doi-asserted-by":"crossref","first-page":"e9698","DOI":"10.1097\/MD.0000000000009698","article-title":"Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries","volume":"97","author":"Tierrablanca","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022022313001285400_dkab442-B6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/jac\/dks404","article-title":"Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor","volume":"68","author":"Sharma","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022022313001285400_dkab442-B7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/hiv.12012","article-title":"Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-na\u00efve, HIV-1-infected patients at 48 weeks","volume":"14","author":"Mills","year":"2013","journal-title":"HIV Med"},{"key":"2022022313001285400_dkab442-B8","author":"European AIDS Clinical Society (EACS)","year":"2019"},{"key":"2022022313001285400_dkab442-B9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1096\/fj.09-148676","article-title":"Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection","volume":"24","author":"Leibowitch","year":"2010","journal-title":"FASEB J"},{"key":"2022022313001285400_dkab442-B10","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1096\/fj.14-260315","article-title":"Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project","volume":"29","author":"Leibowitch","year":"2015","journal-title":"FASEB J"},{"key":"2022022313001285400_dkab442-B11","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkx434","article-title":"Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial","volume":"73","author":"de Truchis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2022022313001285400_dkab442-B12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/jac\/dkz555","article-title":"Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients","volume":"75","author":"Calin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022022313001285400_dkab442-B13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1524-4733.2006.00121.x","article-title":"Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version","volume":"9","author":"Woodcock","year":"2006","journal-title":"Value Health"},{"key":"2022022313001285400_dkab442-B14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/aid.2008.0203","article-title":"Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression","volume":"25","author":"Rudy","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022022313001285400_dkab442-B15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/QAD.0b013e32835e1554","article-title":"Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies\/ml or less: week 48 phase III analysis","volume":"27","author":"Molina","year":"2013","journal-title":"AIDS"},{"key":"2022022313001285400_dkab442-B16","first-page":"e00899","article-title":"Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals","volume":"61","author":"Aouri","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022022313001285400_dkab442-B17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FTD.0b013e3182791f8c","article-title":"The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems","volume":"35","author":"Schoenenberger","year":"2013","journal-title":"Ther Drug Monit"},{"key":"2022022313001285400_dkab442-B18","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/17512433.2016.1235972","article-title":"Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients","volume":"9","author":"Punyawudho","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2022022313001285400_dkab442-B19","author":"Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7\/7 Days Per Week in HIV-1 Infected Patients (QUATUOR). Identification number"},{"key":"2022022313001285400_dkab442-B20","volume-title":"Tenth IAS Conference on HIV Science, Mexico City, Mexico, 2019","author":"Landman"},{"key":"2022022313001285400_dkab442-B21","doi-asserted-by":"crossref","first-page":"e10307","DOI":"10.1371\/journal.pone.0010307","article-title":"A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda","volume":"5","author":"Reynolds","year":"2010","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/747\/42587255\/dkab442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/3\/747\/42587255\/dkab442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T15:47:46Z","timestamp":1645631266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/3\/747\/6445130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,28]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,28]]},"published-print":{"date-parts":[[2022,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab442","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,2]]},"published":{"date-parts":[[2021,11,28]]}}}